Impact of a yoga intervention over 6, 12, and 24 months in sedentary climacteric women with metabolic syndrome

Long-term effects of a structured Shivam Yoga intervention on symptoms, metabolic, and anthropometric parameters in sedentary climacteric women

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN86106594

Enrollment

102

Registered

2025-10-30

Start date

2018-11-01

Completion date

Unknown

Last updated

2025-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic syndrome and climacteric symptoms in sedentary middle-aged women. Nutritional, Metabolic, Endocrine

Interventions

Participants are randomly assigned 1:1 to a yoga intervention or control group. The yoga group attends twice-weekly 60-minute Shivam Yoga sessions (postures, breathing, relaxation, meditation) for 24

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Women aged 40–65 years. 2. Diagnosed with metabolic syndrome according to the Joint Interim Statement (JIS) criteria. 3. Sedentary lifestyle (no regular physical activity in the previous 6 months). 4. Willingness to participate and provide written informed consent.

Exclusion criteria

Exclusion criteria: Women reporting significant lifestyle changes, initiation of exercise programs, or new medication use were excluded from the analysis.

Design outcomes

Primary

Measure	Time frame
Prevalence of metabolic syndrome measured using Joint Interim Statement (JIS) diagnostic criteria at baseline, 6, 12, and 24 months.	—

Secondary

Measure	Time frame
1. Fasting glucose, triglycerides, and HDL cholesterol measured using enzymatic spectrophotometric assays at baseline, 6, 12, and 24 months 2. Waist circumference measured using a standard tape at the midpoint between the lower rib and iliac crest at baseline, 6, 12, and 24 months 3. Systolic and diastolic blood pressure measured using a digital wrist sphygmomanometer (Bioland® - 3005) at baseline, 6, 12, and 24 months 4. Climacteric symptoms measured using the Kupperman Index questionnaire at baseline, 6, 12, and 24 months	—

Measure

Time frame

1. Fasting glucose, triglycerides, and HDL cholesterol measured using enzymatic spectrophotometric assays at baseline, 6, 12, and 24 months 2. Waist circumference measured using a standard tape at the midpoint between the lower rib and iliac crest at baseline, 6, 12, and 24 months 3. Systolic and diastolic blood pressure measured using a digital wrist sphygmomanometer (Bioland® - 3005) at baseline, 6, 12, and 24 months 4. Climacteric symptoms measured using the Kupperman Index questionnaire at baseline, 6, 12, and 24 months

—

Countries

Brazil

Contacts

Public ContactLaura Cota e Souza

laura.cota@aluno.ufop.edu.br-

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026